Gesine Bug

9.7k total citations
141 papers, 4.2k citations indexed

About

Gesine Bug is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Gesine Bug has authored 141 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 46 papers in Molecular Biology and 35 papers in Oncology. Recurrent topics in Gesine Bug's work include Acute Myeloid Leukemia Research (71 papers), Hematopoietic Stem Cell Transplantation (47 papers) and Histone Deacetylase Inhibitors Research (26 papers). Gesine Bug is often cited by papers focused on Acute Myeloid Leukemia Research (71 papers), Hematopoietic Stem Cell Transplantation (47 papers) and Histone Deacetylase Inhibitors Research (26 papers). Gesine Bug collaborates with scholars based in Germany, United States and France. Gesine Bug's co-authors include Oliver G. Ottmann, Erhard Seifried, Torsten Tonn, Dieter Hoelzer, Hans Klingemann, A Romański, Martin Ruthardt, Sven Becker, Wolf‐Karsten Hofmann and Ulrike Koehl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Gesine Bug

129 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gesine Bug Germany	35	2.3k	1.6k	1.3k	1.2k	648	141	4.2k
Geoffrey L. Uy United States	32	2.9k 1.3×	1.6k 1.0×	1.5k 1.2×	900 0.7×	536 0.8×	214	4.6k
Carol Ann Huff United States	31	2.4k 1.1×	1.8k 1.1×	1.8k 1.4×	966 0.8×	438 0.7×	107	4.3k
Marco Gobbi Italy	33	1.9k 0.8×	1.0k 0.6×	1.3k 1.0×	969 0.8×	896 1.4×	171	3.9k
Norio Asou Japan	34	2.9k 1.3×	2.4k 1.5×	783 0.6×	1.0k 0.8×	836 1.3×	180	4.8k
Reinier Raymakers Netherlands	33	1.8k 0.8×	1.5k 1.0×	891 0.7×	748 0.6×	745 1.1×	109	3.6k
Alice Bertaina Italy	35	1.5k 0.7×	628 0.4×	996 0.8×	1.8k 1.5×	614 0.9×	141	3.6k
Franca Falzetti Italy	27	2.5k 1.1×	691 0.4×	1.0k 0.8×	2.1k 1.7×	865 1.3×	97	4.3k
Michael Morgan Germany	32	2.2k 1.0×	2.5k 1.6×	1.5k 1.2×	1.0k 0.8×	794 1.2×	106	5.0k
Javier Briones Spain	35	1.0k 0.5×	831 0.5×	1.9k 1.5×	1.7k 1.4×	957 1.5×	161	4.5k
Vesna Najfeld United States	38	2.1k 0.9×	1.5k 0.9×	470 0.4×	636 0.5×	1.6k 2.5×	140	4.0k

Countries citing papers authored by Gesine Bug

Since Specialization

Citations

This map shows the geographic impact of Gesine Bug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gesine Bug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gesine Bug more than expected).

Fields of papers citing papers by Gesine Bug

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gesine Bug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gesine Bug. The network helps show where Gesine Bug may publish in the future.

Co-authorship network of co-authors of Gesine Bug

This figure shows the co-authorship network connecting the top 25 collaborators of Gesine Bug. A scholar is included among the top collaborators of Gesine Bug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gesine Bug. Gesine Bug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Simone, Martin Wermke, Vladan Vučinić, et al.. (2025). First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. Cancers. 17(18). 2968–2968.

Giebel, Sebastian, Myriam Labopin, Zinaida Perić, et al.. (2024). Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT. Transplantation and Cellular Therapy. 31(1). 14.e1–14.e10.

Hehlgans, Stephanie, et al.. (2024). Irradiation alters extracellular vesicle microRNA load in the serum of patients with leukaemia. Strahlentherapie und Onkologie. 201(2). 173–184. 1 indexed citations

Gagelmann, Nico, Matthias Stelljes, Igor Wolfgang Blau, et al.. (2024). Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. American Journal of Hematology. 99(8). 1540–1549. 2 indexed citations

Jäger, Paul, Johanna Tischer, Alessia Fraccaroli, et al.. (2024). Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers. 16(3). 532–532. 6 indexed citations

Kayser, Sarah, Emilia Salzmann‐Manrique, Hubert Serve, et al.. (2024). Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation. Frontiers in Immunology. 15. 1413927–1413927.

Cremer, Anjali, Julius C. Enßle, Fabian Lang, et al.. (2023). Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML. Annals of Hematology. 102(10). 2903–2908. 2 indexed citations

Bug, Gesine, Myriam Labopin, Riitta Niittyvuopio, et al.. (2023). Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation. 58(6). 710–716. 5 indexed citations

Fischer, D, et al.. (2023). Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome–negative acute lymphoblastic leukemia. Annals of Hematology. 103(2). 489–498. 2 indexed citations

10.

Bazarbachi, Ali, Myriam Labopin, Tobias Gedde‐Dahl, et al.. (2023). Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3 -ITD and Wild-type NPM1 : A Report from the EBMT Acute Leukemia Working Party. Clinical Cancer Research. 29(21). 4441–4448. 4 indexed citations

11.

Loke, Justin, Myriam Labopin, Charles Craddock, et al.. (2022). Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 128(15). 2922–2931. 31 indexed citations

12.

Schmid, Christoph, Jürgen Kuball, & Gesine Bug. (2021). Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. Journal of Clinical Oncology. 39(5). 397–418. 28 indexed citations

13.

Bazarbachi, Ali, Christoph Schmid, Myriam Labopin, et al.. (2020). Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research. 26(24). 6475–6482. 39 indexed citations

14.

Hirschbühl, Klaus, Myriam Labopin, Mohamed Houhou, et al.. (2020). Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation. 56(5). 1190–1199. 14 indexed citations

15.

Lang, Fabian, Lydia Wunderle, Eberhard Schleyer, et al.. (2020). A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology. 21(1). 70–70. 28 indexed citations

16.

Mohr, Sebastian, Martin Schmitt, Alexandra Walter, et al.. (2017). LSD1 Inhibition Leads to Differentiation in Hoxa9/Meis1- but Not in MN1-Induced Acute Myeloid Leukemia. Blood. 130. 1246–1246. 1 indexed citations

17.

Middeke, Jan Moritz, Dietrich W. Beelen, Michael Stadler, et al.. (2012). Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−. Blood. 120(12). 2521–2528. 42 indexed citations

18.

Bolck, Hella Anna, Marc Buchwald, Harald Polzer, et al.. (2012). Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors. Molecular Cancer Therapeutics. 11(11). 2373–2383. 42 indexed citations

19.

Boehrer, Simone, Lionel Adès, Nicolas Tajeddine, et al.. (2009). Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene. 28(22). 2205–2218. 43 indexed citations

20.

Bug, Gesine, Markus Ritter, Barbara Waßmann, et al.. (2005). Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia. Cancer. 104(12). 2717–2725. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact